Denosumab-associated osteonecrosis of the jaw: earlier onset after switch from zoledronic acid

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1920卷 / 1期
关键词：
D O I：
10.1007/s40278-022-21546-5
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 9
相关论文
共 50 条
  • [41] Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study
    Kang, Ji-Yeon
    Kim, Sang-Yup
    Lim, Jae-Seok
    Kim, Jwa-Young
    Jin, Ga-Youn
    Lee, Yeon-Jung
    Lee, Eun-Young
    MAXILLOFACIAL PLASTIC AND RECONSTRUCTIVE SURGERY, 2023, 45 (01)
  • [42] Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis
    Bagan, J.
    Peydro, A.
    Calvo, J.
    Leopoldo, M.
    Jimenez, Y.
    Bagan, L.
    ORAL DISEASES, 2016, 22 (04) : 324 - 329
  • [43] Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy
    Kastritis, Efstathios
    Melea, Pelagia
    Bagratuni, Tina
    Melakopoulos, Ioannis
    Gavriatopoulou, Maria
    Roussou, Maria
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2304 - 2309
  • [44] Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy
    Melea, Pelagia
    Bagratuni, Tina
    Terpos, Evangelos
    Eleutherakis-Papaiakovou, Evangelos
    Gavriatopoulou, Maria
    Melakopoulos, Ioannis
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    BLOOD, 2014, 124 (21)
  • [45] Risk factors for developing osteonecrosis of the jaw (ONJ) in patients receiving denosumab or zoledronic acid for bone metastases: Results from three phase 3 trials
    Brown, J.
    Saad, F.
    Stopeck, A.
    Fizazi, K.
    Henry, D.
    Diel, I.
    De Boer, R.
    Wang, H.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S268 - S269
  • [46] Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab
    Francini, Filippo
    Pascucci, Alessandra
    Francini, Edoardo
    Miano, Salvatora Tindara
    Bargagli, Gianluca
    Ruggiero, Grazia
    Petrioli, Roberto
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2011, 142 (05): : 506 - 513
  • [47] Pamidronic acid/zoledronic acidAuditory canal and jaw osteonecrosis: case report
    Reactions Weekly, 2006, 1088 (1) : 17 - 17
  • [48] Alendronic-acid/zoledronic-acidMedication-related osteonecrosis of the jaw
    Reactions Weekly, 2024, 1991 (1) : 20 - 20
  • [49] Pharmacovigilance cohort study of osteonecrosis of the jaw and serious infection among cancer patients treated with denosumab or zoledronic acid in Denmark, Norway, and Sweden
    Ehrenstein, Vera
    Heide-Jorgensen, Uffe
    Schiodt, Morten
    Akre, Olof
    Herlofson, Bente B.
    Hansen, Svein
    Wexell, Cecilia Larsson
    Norholt, Sven Erik
    Tretli, Steinar
    Kjellman, Anders
    Sorensen, Henrik T.
    Glennane, Anthony
    Lowe, Kimberly
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 461 - 461
  • [50] Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
    Hiroaki Ikesue
    Kohei Doi
    Mayu Morimoto
    Masaki Hirabatake
    Nobuyuki Muroi
    Shinsuke Yamamoto
    Toshihiko Takenobu
    Tohru Hashida
    Supportive Care in Cancer, 2022, 30 : 2341 - 2348
12345